CERO
NASDAQCERo Therapeutics Holdings Inc.
$0.10-1.66 (-94.51%)
News25/Ratings1
Price$0.10+0.00 (+0.00%)
2026-01-162026-04-22
News · 26 weeks52+800%
2025-10-262026-04-19
Mix1890d
- SEC Filings10(56%)
- Other4(22%)
- Leadership2(11%)
- Insider2(11%)
Latest news
25 items- INSIDERSEC Form 4 filed by Francois Eric4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
- INSIDERSEC Form 3 filed by new insider Francois Eric3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
- SECSEC Form 424B3 filed by CERo Therapeutics Holdings Inc.424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- SECSEC Form 10-K filed by CERo Therapeutics Holdings Inc.10-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- SECSEC Form 424B3 filed by CERo Therapeutics Holdings Inc.424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- SECCERo Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- PRCERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 TrialStudy will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF) SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB:CERO) ("CERo" or the "Company") an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has dosed the third patient in the second cohort (sixth patient overall) in its Phase 1 CER-1236 clinical trial in hematologic malignancies. The patient had MDS that evolved to acute myeloid leukemia (AML). The trial was recently expanded to include earlier forms of MDS and myelof
- SECSEC Form NT 10-K filed by CERo Therapeutics Holdings Inc.NT 10-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- PRCERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 TrialTrial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MF SOUTH SAN FRANCISCO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB:CERO) ("CERo" or the "Company") an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has dosed the second patient in the second cohort (fifth patient overall) in its Phase 1 CER-1236 clinical trial in hematologic malignancies, including acute myeloid leukemia (AML), with planned expansion into myelodysplastic syndromes (MDS) and myelofibrosis (MF). With more than seven d
- PRCERo Therapeutics Provides Shareholder UpdateOngoing activities, including new engagement to relist on Nasdaq, new board member, continued advancement of Phase 1 trial into MDS patients, strategic engagement, and continued support from lead investor, underscore the Company's operational momentum SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, provides an update through the letter to stockholders and stakeholders from CEO Chris Ehrlich: To our stockholders and stakeholders: Following our recent Form 8-K filing confirming receipt of convertible deb
- SECSEC Form 424B3 filed by CERo Therapeutics Holdings Inc.424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- PRCERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of DirectorsSOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company's Board of Directors. "Eric's decades of financial, transactional and operational experience will make an immediate impact to CERo's board of directors," said Chris Ehrlich, Company Chairman and Chief Executive Officer. "Furthermore, his expertise in capital raising, M&A, and business development will be an impactful addition at this stage of our development." Mr. Francois is an executive with over 25
- SECCERo Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Changes in Registrant's Certifying Accountant, Leadership Update8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- SECSEC Form 424B3 filed by CERo Therapeutics Holdings Inc.424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- SECCERo Therapeutics Holdings Inc. filed SEC Form 8-K: Other Events8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- PRCERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML PatientPoster to be presented at Tandem Meeting of the American Society of Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) on February 5, 2026 SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces a presentation highlighting data to date from the Company's Phase 1 clinical trial, called CERTAIN-T, of its lead compound, CER-1236. Reflective of the Company's recent clinical update, the data highlight results from the first cohort
- SECSEC Form 424B3 filed by CERo Therapeutics Holdings Inc.424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- SECCERo Therapeutics Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
- INSIDERSEC Form 4 filed by Director Laporte Kathleen4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
- INSIDERSEC Form 4 filed by Chief Development Officer Pierce Kristen4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
- INSIDERSEC Form 4 filed by Director Patel Shami4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
- INSIDERSEC Form 4 filed by Director Rolfe Lindsey4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
- INSIDERSEC Form 4 filed by Director Atwood Brian G4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
- INSIDERSEC Form 4 filed by Director Byrnes Michael4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
- INSIDERSEC Form 4 filed by Chairman and CEO Ehrlich Christopher B4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)